CellCarta expands it proteomics portfolio with the acquisition of next-generation immuno-MRM assays from Precision Assays
This acquisition solidifies CellCarta’s leadership position in proteomics services with a unique combination of validated set of reagents and multiplex assays, including pathway specific off-the-shelf panels, allowing for clinical protein quantification covering a comprehensive range of immuno-oncology targets. CellCarta, a leading global provider of precision medicine laboratory services, announced today the acquisition of the…
